Literature DB >> 1606554

Cytogenetic studies in acute nonlymphocytic leukemia.

F Solé1, M R Caballín, M D Coll, S Woessner, C Besses, J Sans-Sabrafen, J Egozcue.   

Abstract

Cytogenetic studies were performed in 74 untreated patients with acute nonlymphocytic leukemia (ANLL) between 1985 and 1988. Among 56 patients who were examined successfully at the time of diagnosis, 36 had abnormal karyotypes (64.2%). The distribution of chromosome abnormalities was uneven, according to the categories of the French-American-British (FAB) nomenclature. The highest frequency of chromosome abnormalities was observed in ANLL M4 with bone marrow (BM) eosinophilia (M4Eo). Numerical changes were observed in 11 cases; chromosome 8 was most frequently gained (11 patients), whereas chromosome 7 was most frequently lost (4 patients). Structural rearrangements were detected in 18 patients. Involvement of 16q22 was noted in 7 patients, 5q- was noted in 5, t(8;21) in 3, t(1;7) in 2, del(20) in 2, and involvement of 11q23 was noted in 2. The inversion of chromosome 16 was restricted to the M4Eo subtype. This study identified a novel abnormality [inv(2) (p11.2q11.2)] that had not been reported previously by other investigators.

Entities:  

Mesh:

Year:  1992        PMID: 1606554     DOI: 10.1016/0165-4608(92)90002-p

Source DB:  PubMed          Journal:  Cancer Genet Cytogenet        ISSN: 0165-4608


  2 in total

1.  New recurrent balanced translocations in acute myeloid leukemia and myelodysplastic syndromes: cancer and leukemia group B 8461.

Authors:  Alison Walker; Krzysztof Mrózek; Jessica Kohlschmidt; Kathleen W Rao; Mark J Pettenati; Lisa J Sterling; Guido Marcucci; Andrew J Carroll; Clara D Bloomfield
Journal:  Genes Chromosomes Cancer       Date:  2012-12-10       Impact factor: 5.006

2.  Identification of SUPT3H as a novel 8q24/MYC partner in blastic plasmacytoid dendritic cell neoplasm with t(6;8)(p21;q24) translocation.

Authors:  Y Nakamura; H Kayano; E Kakegawa; H Miyazaki; T Nagai; Y Uchida; Y Ito; N Wakimoto; S Mori; M Bessho
Journal:  Blood Cancer J       Date:  2015-04-10       Impact factor: 11.037

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.